Clinical Trial Update: Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab and bevacizumab with chemotherapy followed by pembrolizumab, bevacizumab, and olaparib in recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Ovarian Epithelial Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Kosei Hasegawa, MD, PhD | Conditions: Carcinoma, Ovarian Epithelial | Phase 2 | Status: UNKNOWN